In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million.
OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution Oxigene
Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye. In 2010, OXiGENE acquired VaxGen, Inc
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) OXiGENE acquired VaxGen